Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Florida now leads the nation in property insurance costs, with many homeowners paying more than $10,000 a year for shrinking coverage and higher deductibles. Despite nearly half of hurricane‑related claims ending with no payout and appeals failing over 90% of the time, state leaders say reforms “need more time to work.” With key relief bills stalled and real estate professionals feeling the shockwaves, experts warn that legislative inaction is deepening a crisis that threatens homeownership and the state’s economic stability.
Banks are finally calling in billions tied to troubled commercial real estate loans, pushing delinquency rates to historic highs and ending years of “extend and pretend.” With more than 12% of office loans now delinquent and $875 billion in commercial debt maturing in 2026, regional banks and property owners are facing mounting pressure. As valuations drop and refinancing becomes harder, experts warn that tighter lending standards and broader economic ripple effects are on the horizon—making strategic preparation essential for today’s real estate and finance professionals.
Florida policyholders are getting rare good news: the Florida Insurance Guaranty Association is ending its 1% emergency insurance assessment on October 1—two years ahead of schedule. The decision follows a calmer hurricane season, fewer insurer insolvencies, and growing market stability. The early termination is expected to save Floridians up to $650 million, with the average homeowner seeing about $31 in annual savings. This marks another milestone in the state’s insurance market recovery after major legislative reforms in 2022 and 2023.
The real estate industry has officially moved past its AI honeymoon phase. What began as a fun, optional tool has quietly become the backbone of how agents create content, communicate with clients, and market properties. But with that shift comes rising concern about authenticity, legal risks, and whether consumers will start questioning what they’re really paying agents for. As AI blends into everything from listing descriptions to client advice, professionals now face a new challenge: proving the human value behind the technology.
After years of volatility, industry analysts say commercial real estate may finally be on the verge of a major comeback. Investment activity is rising, leasing demand is strengthening, and key cities like Manhattan are leading a broader national recovery. With vacancy rates expected to drop and high‑quality buildings outperforming the rest, 2026 is shaping up to be the turning point investors and professionals have been waiting for.
AM Best warns that the property and casualty insurance market is heading into a more challenging 2026 as premium growth slows, inflation drives up claims costs, and combined ratios rise. Despite a strong 2025, moderating rates, higher repair and construction expenses, and ongoing reserve deficiencies are pressuring profitability. While commercial lines and personal lines both feel the strain, the E&S market continues to expand as traditional carriers pull back. This shifting landscape highlights the need for insurance professionals to stay sharp, informed, and adaptable.
